Adverse Drug Effects
Pegylated interferon may cause vision disorders in chronic hepatitis C patients
Published in Hepatitis Weekly, October 25th, 2004
"Ocular toxicity, including retinopathy, optic neuropathy and ocular loss, has been infrequently (<1%) reported as a potentially serious adverse event associated with standard interferon therapy. The new pegylated interferons have improved pharmacokinetics which translates to better antiviral efficacy, however, this improved pharmacokinetic profile also has the potential to alter the frequency and extent of their adverse events," according to researchers in the United States.
"We describe a case of chronic hepatitis C infection that developed visual complaints after 1...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-10-25)
More Articles from Hepatitis Weekly
- Bioreactors
Escherichia coli produces purified hepatitis C virus NS5A protein - Chronic Hepatitis C
Hepatitis C virus infection does not stimulate hepatic interferon production - Gastroenterology
Liver enzymes monitor post-surgical liver function in those with HCV antibody - Hepatitis B Virus Therapy
Small interfering RNA stifles the production of hepatitis B virus - Cancer Research
Study questions link between SV40 and pleural mesothelioma - Collaborations
Companies to develop of Genelabs' hepatitis C compounds - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
